- The FDA has granted Fast Track designation to Pfizer's (NYSE:PFE) investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD).
- Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
- PF-06939926 is currently being evaluated in a Phase 1 study. A Phase 3 should launch in the coming weeks.
- Related ticker: Sarepta Therapeutics (NASDAQ:SRPT)
- https://seekingalpha.com/news/3618726-pfizer-gene-therapy-fast-trackd-for-duchenne-muscular-dystrophy
Thursday, October 1, 2020
Pfizer gene therapy Fast Track'd for Duchenne muscular dystrophy
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.